SFMBT1 Polyklonaler Antikörper
SFMBT1 Polyklonal Antikörper für WB, Indirect ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human, Maus, Ratte
Anwendung
WB, Indirect ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 23631-1-PBS
Synonyme
Geprüfte Anwendungen
Produktinformation
23631-1-PBS bindet in WB, Indirect ELISA SFMBT1 und zeigt Reaktivität mit human, Maus, Ratten
| Getestete Reaktivität | human, Maus, Ratte |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Polyklonal |
| Typ | Antikörper |
| Immunogen | SFMBT1 fusion protein Ag20417 |
| Vollständiger Name | Scm-like with four mbt domains 1 |
| Berechnetes Molekulargewicht | 866 aa, 98 kDa |
| Beobachtetes Molekulargewicht | 93-98 kDa |
| GenBank-Zugangsnummer | BC014614 |
| Gene symbol | SFMBT1 |
| Gene ID (NCBI) | 51460 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Antigen-affinitätsgereinigt |
| Lagerungspuffer | PBS only |
| Lagerungsbedingungen | Store at -80°C. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
Scm-like with four MBT domains protein 1 (SFMBT1) is also named as Renal ubiquitous protein 1 (RU1). SFMBT1 is a transcriptional repressor that associates with chromatin and interacts with the N-terminal tail of histone H3 (PMID: 17599839). SFMBT1 forms a complex with Lys-specific demethylase 1 (LSD1) and they are believed to act together in combination with RNA polymerase II in the transcriptional regulation of histone genes (PMID: 23592795). SFMBT1 is up-regulated in CRC tumor tissues and cells and may be associated with drug resistance (PMID: 35577773). SFMBT1 regulates the expression and interacts with key genes involved in heart muscle and artery development (PWWP2A, as well as myogenic differentiation (MYOD, SIX2) (PMID: 35483874). Testes, endocrine glands, and blood are tissues that highly express SFMBT1 (PMID: 25613900). SFMBT1 is also highly expressed in skeletal muscles specifically in undifferentiated myoblasts, and this expression starts diminishing during muscle differentiation (PMID: 23349461).

